Criteria of complete remission from trophoblastic neoplasia with the use of human chorionic gonadotropin (HCG) excretion pattern as a parameter.
The excretion pattern of human chorionic gonadotropin (hCG) or luteinizing hormone (LH) was observed in the urine of 77 patients with trophoblastic neoplasia, 109 with complete remission from trophoblastic neoplasia, and 94 with no trophoblastic neoplasia, when the anti-beta-subunit hCG system radioimmunoassay (anti-beta-subunit RIA), which specifically measured hCG was used. The sensitivity of anti-beta-subunit RIA was limited to urinary hCG 16 mIL/ml from the specificity of the anti-beta-subunit serum. Luteinizing hormone in the urine of patients with complete remission and in normal menstrual, postmenopausal, and castrated women was less than 16 mIU/ml in most cases. The excretion pattern of urinary hCG in the patients undergoing treatment for trophoblastic neoplasia was more clearly comprehended with the anti-beta-subunit RIA as compared with the anti-hCH RIA. The criteria for judgment of complete remission were that the hCG value dropped to less than 16 mIU/ml and that cellular response was not observed at least in the last two courses.
D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology; D002822:Choriocarcinoma / Q000188:drug therapy / Q000652:urine*; D006063:Chorionic Gonadotropin / Q000652:urine*; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy / Q000652:urine*; D007986:Luteinizing Hormone / Q000652:urine; D008598:Menstruation; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011247:Pregnancy; D011863:Radioimmunoassay; D012008:Recurrence; D012075:Remission, Spontaneous; D014328:Trophoblastic Neoplasms / Q000188:drug therapy / Q000652:urine*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000652:urine*
D000970:Antineoplastic Agents; D006063:Chorionic Gonadotropin; D007986:Luteinizing Hormone